Denali TherapeuticsDNLI
DNLI
About: Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Employees: 486
0
Funds holding %
of 7,429 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
145% more call options, than puts
Call options by funds: $1.54M | Put options by funds: $630K
29% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 63
22% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 37
6% more capital invested
Capital invested by funds: $1.81B [Q1] → $1.92B (+$108M) [Q2]
2.77% more ownership
Funds ownership: 91.5% [Q1] → 94.27% (+2.77%) [Q2]
2% more funds holding
Funds holding: 221 [Q1] → 225 (+4) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$30
93%
upside
Avg. target
$30
93%
upside
High target
$30
93%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Morgan Stanley Matthew Harrison | 93%upside $30 | Overweight Maintained | 18 Aug 2025 |
Financial journalist opinion
Based on 3 articles about DNLI published over the past 30 days
Positive
Kiplinger
1 week ago
The Best Small-Cap Stocks to Buy Now
Wall Street's best small-cap stocks to buy include biotech, real estate and software names.
Neutral
Zacks Investment Research
1 week ago
DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26
Denali Therapeutics posts narrower-than-expected Q2 loss. The company advances multiple rare disease therapies toward potential approvals.
Neutral
GlobeNewsWire
2 weeks ago
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launch DNL126 accelerated approval path for Sanfilippo syndrome Type A aligned with FDA; Phase 1/2 study nearing completion of enrollment; planning underway for a global Phase 3 confirmatory study On track to submit regulatory applications in 2025 to begin clinical testing of one to two additional TransportVehicleTM (TV)-enabled programs Preclinical research on ATV:Abeta program for Alzheimer's disease published in the journal Science SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the second quarter ended June 30, 2025, and provided business highlights.
Positive
Zacks Investment Research
1 month ago
DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review
Denali's lead drug for Hunter syndrome wins FDA Priority Review, marking a key step toward commercial-stage status.
Neutral
GlobeNewsWire
1 month ago
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
FDA assigns PDUFA target action date of January 5, 2026, for decision on accelerated approval Tividenofusp alfa is designed to deliver missing enzyme to entire body and cross blood-brain barrier into the brain Tividenofusp alfa leads company's broader TransportVehicle™-enabled pipeline SOUTH SAN FRANCISCO, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) seeking accelerated approval for tividenofusp alfa for the treatment of Hunter syndrome (mucopolysaccharidoses type II, or MPS II), a rare and progressive genetic disorder.
Positive
Zacks Investment Research
2 months ago
Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report?
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock?
Negative
Zacks Investment Research
3 months ago
Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus
DNLI reports a wider-than-expected loss for the first quarter of 2025. Denali submits a BLA for tividenofusp alfa under the FDA?
Neutral
GlobeNewsWire
3 months ago
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2025, and provided business highlights.
Positive
Zacks Investment Research
3 months ago
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
Positive
Zacks Investment Research
4 months ago
DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up
Denali stock up as it begins rolling BLA submission with the FDA for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome.
Charts implemented using Lightweight Charts™